ProMIS Neurosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGProMIS Neurosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 39), showing significant lag compared to the market leaders. Earnings growth of 76% provides fundamental context to the price action. Investors should exercise caution due to high volatility (104% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.24 | +2.82% | ABOVE |
| 50 SMA | $10.58 | -0.52% | BELOW |
| 100 SMA | $13.64 | -22.83% | BELOW |
| 150 SMA | $11.98 | -12.14% | BELOW |
| 200 SMA | $11.71 | -10.10% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PMN in an uptrend right now?
PMN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is PMN overbought or oversold?
PMN's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.
Is PMN outperforming the market?
PMN has a Relative Strength (RS) Rating of 39 out of 99. PMN is currently lagging the broader market.
Where is PMN in its 52-week range?
PMN is trading at $10.53, which is 26% of its 52-week high ($39.75) and 13% above its 52-week low ($6.27).
How volatile is PMN?
PMN has a Beta of 1.04 and 52-week volatility of 104%. It's more volatile than the S&P 500 - expect bigger swings.